Cas:936551-05-2 2-[2-[[3-[2-(dimethylamino)ethyl]-1H-indol-5-yl]methyl]-5-(1H-1,2,4-triazol-1-ylmethyl)-1Hindol- 3-yl]-N,N-dimethylethanamine manufacturer & supplier

We serve Chemical Name:2-[2-[[3-[2-(dimethylamino)ethyl]-1H-indol-5-yl]methyl]-5-(1H-1,2,4-triazol-1-ylmethyl)-1Hindol- 3-yl]-N,N-dimethylethanamine CAS:936551-05-2 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

2-[2-[[3-[2-(dimethylamino)ethyl]-1H-indol-5-yl]methyl]-5-(1H-1,2,4-triazol-1-ylmethyl)-1Hindol- 3-yl]-N,N-dimethylethanamine

Chemical Name:2-[2-[[3-[2-(dimethylamino)ethyl]-1H-indol-5-yl]methyl]-5-(1H-1,2,4-triazol-1-ylmethyl)-1Hindol- 3-yl]-N,N-dimethylethanamine
CAS.NO:936551-05-2
Synonyms:2-[2-[[3-[2-(dimethylamino)ethyl]-1H-indol-5-yl]methyl]-5-(1H-1,2,4-triazol-1-ylmethyl)-1Hindol- 3-yl]-N,N-dimethylethanamine
Molecular Formula:N/A
Molecular Weight:N/A
HS Code:

Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:
Exact Mass:
LogP:

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:


Contact us for information like 2-[2-[[3-[2-(dimethylamino)ethyl]-1H-indol-5-yl]methyl]-5-(1H-1,2,4-triazol-1-ylmethyl)-1Hindol- 3-yl]-N,N-dimethylethanamine chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,2-[2-[[3-[2-(dimethylamino)ethyl]-1H-indol-5-yl]methyl]-5-(1H-1,2,4-triazol-1-ylmethyl)-1Hindol- 3-yl]-N,N-dimethylethanamine physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2-[2-[[3-[2-(dimethylamino)ethyl]-1H-indol-5-yl]methyl]-5-(1H-1,2,4-triazol-1-ylmethyl)-1Hindol- 3-yl]-N,N-dimethylethanamine Use and application,2-[2-[[3-[2-(dimethylamino)ethyl]-1H-indol-5-yl]methyl]-5-(1H-1,2,4-triazol-1-ylmethyl)-1Hindol- 3-yl]-N,N-dimethylethanamine technical grade,usp/ep/jp grade.


Related News: The memo denies the company made false statements to the FDA. In their complaint, employees said they were broadly concerned that quality control documents the FDA requires companies to maintain had been rewritten or fabricated. The employees did not specify whether these materials had been shown to the FDA. 2-[2-[[3-[2-(dimethylamino)ethyl]-1H-indol-5-yl]methyl]-5-(1H-1,2,4-triazol-1-ylmethyl)-1Hindol- 3-yl]-N,N-dimethylethanamine manufacturer The memo denies the company made false statements to the FDA. In their complaint, employees said they were broadly concerned that quality control documents the FDA requires companies to maintain had been rewritten or fabricated. The employees did not specify whether these materials had been shown to the FDA. 2-[2-[[3-[2-(dimethylamino)ethyl]-1H-indol-5-yl]methyl]-5-(1H-1,2,4-triazol-1-ylmethyl)-1Hindol- 3-yl]-N,N-dimethylethanamine supplier This part is mainly anti-tumor drugs, prostate drugs and certain hormone drugs. 2-[2-[[3-[2-(dimethylamino)ethyl]-1H-indol-5-yl]methyl]-5-(1H-1,2,4-triazol-1-ylmethyl)-1Hindol- 3-yl]-N,N-dimethylethanamine vendor AbbVie and Johnson & Johnson already boast three FDA-approved regimens for Imbruvica in newly diagnosed chronic lymphocytic leukemia (CLL). Now, the pair aims to add another to the drug’s label, one that could shorten the time patients need to stay on treatment. 2-[2-[[3-[2-(dimethylamino)ethyl]-1H-indol-5-yl]methyl]-5-(1H-1,2,4-triazol-1-ylmethyl)-1Hindol- 3-yl]-N,N-dimethylethanamine factory AbbVie and Johnson & Johnson already boast three FDA-approved regimens for Imbruvica in newly diagnosed chronic lymphocytic leukemia (CLL). Now, the pair aims to add another to the drug’s label, one that could shorten the time patients need to stay on treatment.